

Behavioral interventions to reduce obesity for adults: High-intensity, in-person programs

Health Care: Obesity and Diabetes

Benefit-cost estimates updated December 2019. Literature review updated December 2014.

Current estimates replace old estimates. Numbers will change over time as a result of model inputs and monetization methods.

The WSIPP benefit-cost analysis examines, on an apples-to-apples basis, the monetary value of programs or policies to determine whether the benefits from the program exceed its costs. WSIPP's research approach to identifying evidence-based programs and policies has three main steps. First, we determine "what works" (and what does not work) to improve outcomes using a statistical technique called meta-analysis. Second, we calculate whether the benefits of a program exceed its costs. Third, we estimate the risk of investing in a program by testing the sensitivity of our results. For more detail on our methods, see our [Technical Documentation](#).

Program Description: Behavioral interventions for obesity include behavioral counseling, therapy, and educational components, and often include diet and exercise components as well. For this review of interventions for obese adults, we excluded studies that targeted diabetic populations as well as those aimed at preventing obesity.

Programs in this specific category are delivered to obese adults, and conducted face-to-face, with 12 or more sessions a year for 12 months or more.

Benefit-Cost Summary Statistics Per Participant

Benefits to:

Taxpayers	\$525	Benefit to cost ratio	\$2.93
Participants	\$938	Benefits minus costs	\$1,269
Others	\$325	Chance the program will produce	
Indirect	\$138	benefits greater than the costs	61 %
Total benefits	\$1,926		
Net program cost	(\$656)		
Benefits minus cost	\$1,269		

The estimates shown are present value, life cycle benefits and costs. All dollars are expressed in the base year chosen for this analysis (2018). The chance the benefits exceed the costs are derived from a Monte Carlo risk analysis. The details on this, as well as the economic discount rates and other relevant parameters are described in our [Technical Documentation](#).

Meta-Analysis of Program Effects

Outcomes measured	Treatment age	No. of effect sizes	Treatment N	Adjusted effect sizes and standard errors used in the benefit-cost analysis						Unadjusted effect size (random effects model)	
				First time ES is estimated			Second time ES is estimated			ES	p-value
				ES	SE	Age	ES	SE	Age		
Weight change	50	12	2070	-0.174	0.050	50	0.000	0.012	55	-0.174	0.001
Diastolic blood pressure [^]	50	8	1641	-0.340	0.165	50	n/a	n/a	n/a	-0.340	0.040
Systolic blood pressure [^]	50	8	1641	-0.123	0.047	50	n/a	n/a	n/a	-0.123	0.009
HDL cholesterol [^]	50	7	986	0.049	0.051	50	n/a	n/a	n/a	0.049	0.343
LDL cholesterol [^]	50	7	986	-0.011	0.051	50	n/a	n/a	n/a	-0.011	0.827
Obesity	50	9	1357	-0.238	0.087	50	0.000	0.086	55	-0.238	0.006

[^]WSIPP's benefit-cost model does not monetize this outcome.

Meta-analysis is a statistical method to combine the results from separate studies on a program, policy, or topic in order to estimate its effect on an outcome. WSIPP systematically evaluates all credible evaluations we can locate on each topic. The outcomes measured are the types of program impacts that were measured in the research literature (for example, crime or educational attainment). Treatment N represents the total number of individuals or units in the treatment group across the included studies.

An effect size (ES) is a standard metric that summarizes the degree to which a program or policy affects a measured outcome. If the effect size is positive, the outcome increases. If the effect size is negative, the outcome decreases.

Adjusted effect sizes are used to calculate the benefits from our benefit cost model. WSIPP may adjust effect sizes based on methodological characteristics of the study. For example, we may adjust effect sizes when a study has a weak research design or when the program developer is involved in the research. The magnitude of these adjustments varies depending on the topic area.

WSIPP may also adjust the second ES measurement. Research shows the magnitude of some effect sizes decrease over time. For those effect sizes, we estimate outcome-based adjustments which we apply between the first time ES is estimated and the second time ES is estimated. We also report the unadjusted effect size to show the effect sizes before any adjustments have been made. More details about these adjustments can be found in our [Technical Documentation](#).

Detailed Monetary Benefit Estimates Per Participant

Affected outcome:	Resulting benefits: ¹	Benefits accrue to:				
		Taxpayers	Participants	Others ²	Indirect ³	Total
Obesity	Labor market earnings associated with obesity	\$359	\$844	\$0	\$0	\$1,203
Obesity	Health care associated with obesity	\$156	\$70	\$325	\$78	\$629
Obesity	Mortality associated with obesity	\$10	\$23	\$0	\$388	\$421
Program cost	Adjustment for deadweight cost of program	\$0	\$0	\$0	(\$328)	(\$328)
Totals		\$525	\$938	\$325	\$138	\$1,926

¹In addition to the outcomes measured in the meta-analysis table, WSIPP measures benefits and costs estimated from other outcomes associated with those reported in the evaluation literature. For example, empirical research demonstrates that high school graduation leads to reduced crime. These associated measures provide a more complete picture of the detailed costs and benefits of the program.

²"Others" includes benefits to people other than taxpayers and participants. Depending on the program, it could include reductions in crime victimization, the economic benefits from a more educated workforce, and the benefits from employer-paid health insurance.

³"Indirect benefits" includes estimates of the net changes in the value of a statistical life and net changes in the deadweight costs of taxation.


Detailed Annual Cost Estimates Per Participant

	Annual cost	Year dollars	Summary	
Program costs	\$313	2014	Present value of net program costs (in 2018 dollars)	(\$656)
Comparison costs	\$0	2014	Cost range (+ or -)	25 %

On average, these programs provide approximately 52 contact hours over 24 months, including both group and individual sessions. The average per-participant cost of these programs was computed using contact hours and average Washington State 2014 hourly wages of the appropriate professionals who conducted the intervention (generally dietitians, nurses, general practitioners, or therapists).


The figures shown are estimates of the costs to implement programs in Washington. The comparison group costs reflect either no treatment or treatment as usual, depending on how effect sizes were calculated in the meta-analysis. The cost range reported above reflects potential variation or uncertainty in the cost estimate; more detail can be found in our [Technical Documentation](#).

Benefits Minus Costs Over Time (Cumulative Discounted Dollars)




The graph above illustrates the estimated cumulative net benefits per-participant for the first fifty years beyond the initial investment in the program. We present these cash flows in discounted dollars. If the dollars are negative (bars below \$0 line), the cumulative benefits do not outweigh the cost of the program up to that point in time. The program breaks even when the dollars reach \$0. At this point, the total benefits to participants, taxpayers, and others, are equal to the cost of the program. If the dollars are above \$0, the benefits of the program exceed the initial investment.

Benefits by Perspective Over Time (Cumulative Discounted Dollars)



The graph above illustrates the breakdown of the estimated cumulative benefits (not including program costs) per-participant for the first fifty years beyond the initial investment in the program. These cash flows provide a breakdown of the classification of dollars over time into four perspectives: taxpayer, participant, others, and indirect. "Taxpayers" includes expected savings to government and expected increases in tax revenue. "Participants" includes expected increases in earnings and expenditures for items such as health care and college tuition. "Others" includes benefits to people other than taxpayers and participants. Depending on the program, it could include reductions in crime victimization, the economic benefits from a more educated workforce, and the benefits from employer-paid health insurance. "Indirect benefits" includes estimates of the changes in the value of a statistical life and changes in the deadweight costs of taxation. If a section of the bar is below the \$0 line, the program is creating a negative benefit, meaning a loss of value from that perspective.

Taxpayer Benefits by Source of Value Over Time (Cumulative Discounted Dollars)



The graph above focuses on the subset of estimated cumulative benefits that accrue to taxpayers. The cash flows are divided into the source of the value.

Citations Used in the Meta-Analysis

- Appel, L.J., Clark, J.M., Yeh, H.C., Wang, N.Y., Coughlin, J.W., Daumit, G., Miller, E.R., Dalcin, A., Jerome, G., Geller, S., Noronha, G., Pozefsky, T., Charleston, J., Reynolds, Durkin, N., Rubin, R., Louis, T.A., & Brancati, F.L. (2011). Comparative effectiveness of weight-loss interventions in clinical practice. *The New England Journal of Medicine*, 365(21), 1959-1968.
- Burke, V., Beilin, L.J., Cutt, H.E., Mansour, J., Wilson, A., & Mori, T.A. (2005). Effects of a lifestyle programme on ambulatory blood pressure and drug dosage in treated hypertensive patients: a randomized controlled trial. *Journal of Hypertension*, 23(6), 1241-1249.
- de Vos, B.C., Runhaar, J., & Bierma-Zeinstra, S.M. (2014). Effectiveness of a tailor-made weight loss intervention in primary care. *European Journal of Nutrition*, 53(1), 95-104.
- Eriksson, M.K., Franks, P.W., & Eliasson, M. (2009). A 3-year randomized trial of lifestyle intervention for cardiovascular risk reduction in the primary care setting: the Swedish Bjorknas study. *Plos One*, 4(4), e5195.
- Fitzgibbon, M.L., Stolley, M.R., Schiffer, L., Sharp, L.K., Singh, V., & Dyer, A. (2010). Obesity reduction black intervention trial (ORBIT): 18-month results. *Obesity*, 18(12), 2317-2325.
- Jeffery, R.W., Wing, R.R., Thorson, C., Burton, L.R., Raether, C., Harvey, J., & Mullen, M. (1993). Strengthening behavioral interventions for weight loss: a randomized trial of food provision and monetary incentives. *Journal of Consulting and Clinical Psychology*, 61(6), 1038-1045.
- Kumanyika, S.K., Fassbender, J.E., Sarwer, D.B., Phipps, E., Allison, K.C., Localio, R., Morales, K.H., Wesby, L., Harralson, T., Kessler, R., Tan-Torres, S., Han, X., Tsai, A.G., & Wadden, T.A. (2012). One-year results of the Think Health! study of weight management in primary care practices. *Obesity*, 20(6), 1249-1257.
- The Trials of Hypertension Collaborative Research Group (1997). Effects of Weight Loss and Sodium Reduction Intervention on Blood Pressure and Hypertension Incidence in Overweight People With High-Normal Blood Pressure. *Archives of Internal Medicine*, 157(6), 657-667.
- Ross, R., Lam, M., Blair, S.N., Church, T.S., Godwin, M., Hotz, S.B., Johnson, A., Katzmarzyk, P.T., Levesque, L. & MacDonald, S. (2012). Trial of prevention and reduction of obesity through active living in clinical settings: a randomized controlled trial. *Archives of Internal Medicine*, 172(5), 414-424.
- Silva, M.N., Vieira, P.N., Coutinho, S.R., Minderico, C.S., Matos, M.G., Sardinha, L.B., & Teixeira, P.J. (2010). Using self-determination theory to promote physical activity and weight control: a randomized controlled trial in women. *Journal of Behavioral Medicine*, 33(2), 110-122.
- Vetter, M.L., Wadden, T.A., Chittams, J., Diewald, L.K., Panigrahi, E., Volger, S., Sarwer, D.B., & Moore, R.H.. (2013). Effect of lifestyle intervention on cardiometabolic risk factors: results of the POWER-UP trial. *International Journal of Obesity*, 37(1), 19-24.
- Villareal, D.T., Shah, K., Banks, M.R., Sinacore, D.R., & Klein, S. (2008). Effect of weight loss and exercise therapy on bone metabolism and mass in obese older adults: a one-year randomized controlled trial. *The Journal of Clinical Endocrinology and Metabolism*, 93(6), 2181-2187.
- Wadden, T.A., Volger, S., Sarwer, D.B., Vetter, M.L., Tsai, A.G., Berkowitz, R.I., Kumanyika, S., Schmitz, K.H., Diewald, L.K., Barg, R., Chittams, J., & Moore, R.H. (2011). A two-year randomized trial of obesity treatment in primary care practice. *The New England Journal of Medicine*, 365(21), 1969-1979.
- Wood, P.D., Stefanick, M.L., Williams, P.T., & Haskell, W.L. (1991). The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. *The New England Journal of Medicine*, 325(7), 461-466.
- Woollard, J., Burke, V., Beilin, L.J., Verheijden, M., & Bulsara, M.K. (2003). Effects of a general practice-based intervention on diet, body mass index and blood lipids in patients at cardiovascular risk. *Journal of Cardiovascular Risk*, 10(1), 31-40.

For further information, contact:
(360) 664-9800, institute@wsipp.wa.gov

Printed on 07-05-2022



Washington State Institute for Public Policy

The Washington State Legislature created the Washington State Institute for Public Policy in 1983. A Board of Directors—representing the legislature, the governor, and public universities—governs WSIPP and guides the development of all activities. WSIPP's mission is to carry out practical research, at legislative direction, on issues of importance to Washington State.